Prognostic Significance of JMJD3 Expression in Pleural Mesotheliomas

• Main Authors: Lauren Rask-Nielsen, Sarita Prabhakaran, Ashleigh J. Hocking, Matthew Hussey, Sonja Klebe
• Format: Article
• Language: English
• Published: MDPI AG 2021-07-01
• Series: Journal of Molecular Pathology
• Subjects: JMJD3; immunohistochemistry; pleural; mesothelioma
• Online Access: https://www.mdpi.com/2673-5261/2/3/19

Pleural mesothelioma is a disease associated with asbestos exposure and patients often have poor prognosis. Biomarkers that can stratify tumours more efficiently are much sought after to enable more personalized treatment options and predict prognosis. Jumonji domain-containing protein D3 (JMJD3) has variable expression in a range of tumours. However, there has been much discordance in the immunohistochemical labelling of JMJD3 between cancers at different sites and ambiguity exists regarding its functional significance. Recent evidence suggests that although nuclear expression of JMJD3 has a demethylase role in most cancers, there are also demethylase-independent actions of JMJD3 that need to be explored including its cytoplasmic expression. We analysed JMJD3 labelling in 99 pleural mesothelioma tissues and correlated nuclear and cytoplasmic expression with survival outcomes. We found that low nuclear and high cytoplasmic expression were associated with poor survival outcomes in our cohort (<i>p</i> = 0.014 and <i>p</i> = 0.041, respectively). Additionally, we found that low nuclear expression of JMJD3 was frequent in the sarcomatoid subtype (<i>p</i> < 0.001). Finally, we showed that cytoplasmic labelling is an independent prognostic marker of poor survival. Our cohort only contained a small number of tumours with high cytoplasmic expression of JMJD3, and a larger cohort study may provide clearer stratification.